RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 11.08.2020 | 13:34

Supervisory Board of RHÖN-KLINIKUM AG Appoints Two New Members to Board of Management

DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Personnel/Miscellaneous
11.08.2020 / 13:34
The issuer is solely responsible for the content of this announcement.

Corporate News

Bad Neustadt / Saale | 11th August 2020

 

Supervisory Board of RHÖN-KLINIKUM AG Appoints Two New Members to Board of Management

- Management Board of RHÖN-KLINIKUM AG extended by two members in the course of strategic partnership with Asklepios Kliniken GmbH & Co. KGaA

- Supervisory Board appoints Dr. Christian Höftberger as of 15th August 2020 and Dr. Stefan Stranz as of 1st September 2020 to Board of Management

- Extending Board of Management sets course for consistent implementation of the common goal of a holistic healthcare provider with a sustainable strategy for the future

 

The Supervisory Board of RHÖN-KLINIKUM AG appointed two new members to the Board of Management on 10th August and thus took an important step in setting the course for the strategic partnership. Together with parent company Asklepios RHÖN-KLINIKUM AG wishes to drive its concepts for innovative healthcare forwards with a good portion of positive energy and pioneer new routes in cutting-edge medical care in Germany. The university hospitals in Giessen and Marburg (UKGM) - together the third largest university hospital in Germany - will play a key role here. Already today with its five sites providing maximum and intermediate medical care RHÖN-KLINIKUM AG stands for excellent medical care with a direct link to the two university hospitals with their research institutes. This strength also needs to be exploited in the future for the benefit of our patients and employees. The Supervisory Board also decided at the meeting that no new Chairman or Spokesman of the Management Board should be appointed initially.

Eugen Münch, Chairman of the Supervisory Board of RHÖN-KLINIKUM AG, stated: "With Dr. Christian Höftberger and Dr. Stefan Stranz the Supervisory Board has appointed to the Board of Management of RHÖN-KLINIKUM AG two strong personalities who both have many years of talented management experience in the German healthcare system. The appointments are an important basis for the strategic cooperation between the two companies, in order to achieve more than the addition of skills from two solitaires to create a group that stands for excellent medical care - locally, regionally and for the German hospital market as a whole."

Dr. Höftberger who has a PhD in law has been the Regional Managing Director for Asklepios Kliniken GmbH & Co. KGaA in the German Federal State of Hesse since June 2017. Most recently he took on the Presidency of the Hospital Federation in Hesse (Hessische Krankenhausgesellschaft - HKG). He was already a member of the HKG Board of Management from 2010 to 2014. From 2014 to 2017 Dr. Höftberger worked for the Asklepios Group in Hamburg. Before that he was the Managing Director of Asklepios Klinik Lich GmbH where he successfully moved the company into a strategic position and completed its re-orientation, among other things, and also built up strong links with referring physicians for cooperative medical care. Before moving to Asklepios in 2012 to manage the site in Lich he worked for RHÖN-KLINIKUM AG where his last position was as the Commercial Director at the university hospital in Giessen. Dr. Höftberger studied law at the universities in Vienna and Salzburg.

Dr. Christian Höftberger who will become a member of the Board of Management of RHÖN-KLINIKUM AG as of 15th August 2020 stated: "I am very much looking forward to my new position and being able to work alongside my fellow board members, Dr. Gunther Weiss, Prof. Bernd Griewing and Dr. Stefan Stranz. I am totally convinced that RHÖN will be able to take an important step under the roof of Asklepios and ensure the long-term future of the company which will benefit both patients and employees. RHÖN and Asklepios will strategically complement each other and be strong together in the future. Savings which are made from economies of scale will be used to create new jobs and make investments in modern patient care."

Dr. Stefan Stranz has a degree in macroeconomics and a PhD in medicine and has been the Managing Director of Asklepios Kliniken Hamburg GmbH since November 2019. Before that he worked for Schön-Kliniken where he was the Managing Director who was responsible for North Germany and before that Dr. Stranz was the Managing Director of HELIOS Klinikum Erfurt GmbH. He has been working in the hospital industry for a total of more than 15 years already. Dr. Stranz's appointment to the RHÖN Board of Management is subject to the Supervisory Board of Asklepios Kliniken Hamburg GmbH consenting to his premature departure.

Dr. Stefan Stranz stated: "With RHÖN and Asklepios two great names with a single mission are joining forces. Together we shall develop future-oriented concepts for healthcare and drive them forwards with a good portion of positive energy so that we can continue to offer excellent medical care long into the future. Under the same roof we have the best preconditions for modernising the German hospital market and making the best possible use of the corporate group economies of scale in each and every individual hospital."


-----------------------------------------------------

RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. The hospital group offers excellent medical care with a direct link to universities and research institutes. Over 860,000 patients are treated every year at the five group hospitals located in Bad Berka, Bad Neustadt, Frankfurt (Oder), Giessen and Marburg where more than 18,000 employees work. RHÖN-KLINIKUM AG is currently exploiting the opportunities available to develop new areas of growth. Entering the forward-looking telemedicine market with Medgate Deutschland, the innovative RHÖN campus concept for offering future-orientated healthcare across sectoral boundaries in rural areas as well as consistently extending our gradual corporate digitalisation are key pillars of the corporate strategy.


More information under www.rhoen-klinikum-ag.com

Follow us:

www.twitter.com/rhoenklinikumag

www.xing.com/companies/rhön-klinikumag

www.youtube.com/rhönklinikumag

Contact Persons:

RHÖN-KLINIKUM AG | Head of Corporate Communications and Marketing
Elke Pfeifer
Telephone: +49 9771 65-12110 | E-Mail: elke.pfeifer@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt
Telephone: +49 9771 65-12250 | E-Mail: julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt / Saale, Germany



11.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Unternehmen im Fokus

Wasserstoff-Rendite mit HPS

Spätestens mit Veröffentlichung der nationalen Wasserstoffstrategie rücken sämtliche „Wasserstoff-Unternehmen“ verstärkt in den Fokus der Investoren.
Das in Berlin ansässige Unternehmen HPS Home Power Solutions setzt Wasserstoff als saisonales Speichermedium für das autarke und vollständig CO2-freie Energieversorgungssystem picea® in Ein- bis Zweifamilienhäusern ein.
Dieses weltweit erste Solar-Wasserstoffkraftwerk für zuhause erlaubt mit einer Solaranlage eine dezentrale vollständige Stromversorgung über das gesamte Jahr und unterstützt dabei sogar zusätzlich die Wärmeversorgung im Haus.
Zur Finanzierung des laufenden Markteintritts und des weiteren Wachstums begibt HPS ein Nachrangdarlehen von bis zu 4 Mio. € über die Plattform GLS Crowd und verzinst das eingeworbene Kapital ab einem Einsatz von 250 € mit 7 % über eine Laufzeit von 5 Jahren. Die Zeichnungsfrist beginnt am 03.11.2020 um 10:30 Uhr.

Hinweis gemäß § 12 Abs. 2 Vermögensanlagengesetz: Der Erwerb dieser Vermögensanlage ist mit erheblichen Risiken verbunden und kann zum vollständigen Verlust des eingesetzten Vermögens führen.

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Continental AG: Dr. Elmar Degenhart legt sein Amt als Vorstandsvorsitzender von Continental aus eigenem Entschluss vorzeitig nieder

29. Oktober 2020, 21:05

Aktueller Webcast

HENSOLDT AG

9M 2020 Analyst Call

10. November 2020

Aktuelle Research-Studie

Ahlers AG

Original-Research: Ahlers AG (von GSC Research GmbH): Halten

30. Oktober 2020